cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.p7gmc4
title: Occurrence Download

description: A dataset containing 1225 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Seawater carbonate chemistry and Gadus morhua length, weight and sperm biological processes, 2010"
 ]
}

 The dataset includes 1225 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0048647-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17026/ar/dyrcjp
title: PAN-00176388 - (pseudo) coin brooch composite (two lugs)

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00176388&lt;/p&gt;
description: Modified: 2025-08-04T15:48:35+02:00
DOI: 10.6084/m9.figshare.30610622
title: Understanding the role of COVID-19 vaccination in all-cause healthcare resource utilisation among adults with long COVID in the UK primary care setting: data from the 2022–2023 respiratory virus season

description: The role COVID-19 vaccination on healthcare resource utilization (HCRU) and cost remains unclear, especially during Omicron predominance and among high risk UK populations. A retrospective cohort study using UK The Health Improvement Network (THIN) primary care data included adults (≥18 years) with confirmed or suspected COVID-19 between September 2022 and May 2023. Three cohorts were defined: Highest risk (eligible for two seasonal doses), High Risk (eligible for one dose), and All COVID-19 patients. Long COVID was identified as ≥1 symptom or diagnostic/referral code, ≥4 weeks post COVID-19 diagnosis. Inverse probability of treatment weighting assessed associations between vaccination status (yes/no and time since vaccination) and long COVID, HCRU, and costs. In both Risk Cohorts, COVID-19 vaccination was not associated with long COVID incidence. However, in the High Risk (<i>n</i> = 1,889) and All Patients cohorts (<i>n</i> = 8,507) outpatient specialist referrals were significantly lower in the 3–6-month post-vaccination group versus &gt; 6 months (rate ratio: 0.28; 95% CI: 0.10–0.79, <i>p</i> &lt; 0.05 and 0.46; 95% CI: 0.27–0.79; <i>p</i> ≤ 0.01, respectively). COVID-19 vaccination was not consistently associated with incidence of long COVID or all-cause HCRU. Findings suggest potential subgroup-specific benefits, highlighting the importance of annual vaccination. Further research with larger sample size and longer-term follow-up is warranted.
DOI: 10.6084/m9.figshare.30610622.v2
title: Understanding the role of COVID-19 vaccination in all-cause healthcare resource utilisation among adults with long COVID in the UK primary care setting: data from the 2022–2023 respiratory virus season

description: The role COVID-19 vaccination on healthcare resource utilization (HCRU) and cost remains unclear, especially during Omicron predominance and among high risk UK populations. A retrospective cohort study using UK The Health Improvement Network (THIN) primary care data included adults (≥18 years) with confirmed or suspected COVID-19 between September 2022 and May 2023. Three cohorts were defined: Highest risk (eligible for two seasonal doses), High Risk (eligible for one dose), and All COVID-19 patients. Long COVID was identified as ≥1 symptom or diagnostic/referral code, ≥4 weeks post COVID-19 diagnosis. Inverse probability of treatment weighting assessed associations between vaccination status (yes/no and time since vaccination) and long COVID, HCRU, and costs. In both Risk Cohorts, COVID-19 vaccination was not associated with long COVID incidence. However, in the High Risk (<i>n</i> = 1,889) and All Patients cohorts (<i>n</i> = 8,507) outpatient specialist referrals were significantly lower in the 3–6-month post-vaccination group versus &gt; 6 months (rate ratio: 0.28; 95% CI: 0.10–0.79, <i>p</i> &lt; 0.05 and 0.46; 95% CI: 0.27–0.79; <i>p</i> ≤ 0.01, respectively). COVID-19 vaccination was not consistently associated with incidence of long COVID or all-cause HCRU. Findings suggest potential subgroup-specific benefits, highlighting the importance of annual vaccination. Further research with larger sample size and longer-term follow-up is warranted.
DOI: 10.6084/m9.figshare.30610622.v1
title: Understanding the role of COVID-19 vaccination in all-cause healthcare resource utilisation among adults with long covid in the Uk primary care setting: data from the 2022-2023 respiratory virus season

description: The role COVID-19 vaccination on healthcare resource utilization (HCRU) and cost remains unclear, especially during Omicron predominance and among high risk UK populations. A retrospective cohort study using UK The Health Improvement Network (THIN) primary care data included adults (≥18 years) with confirmed or suspected COVID-19 between September 2022- May 2023. Three cohorts were defined: Highest risk (eligible for two seasonal doses), High Risk (eligible for one dose), and All COVID-19 patients. Long COVID was identified as ≥ 1 symptom or diagnostic/referral code, ≥4 weeks post COVID-19 diagnosis. Inverse probability of treatment weighting assessed associations between vaccination status (yes/no and time since vaccination) and long COVID, HCRU, and costs. In both Risk Cohorts, COVID-19 vaccination was not associated with long COVID incidence. However, in the High Risk (<i>n</i> = 1,889) and All Patients cohorts (<i>n</i> = 8,507) outpatient specialist referrals were significantly lower in the 3–6-month post-vaccination group versus &gt; 6 months (rate ratio: 0.28; 95% CI: 0.10-0.79, <i>p</i> &lt; 0.05 and 0.46; 95% CI: 0.27-0.79; <i>p</i> ≤ 0.01, respectively) COVID-19 vaccination was not consistently associated with incidence of long COVID or all-cause HCRU. Findings suggest potential subgroup-specific benefits, highlighting the importance of annual vaccination. Further research with larger sample size and longer-term follow-up is warranted.
DOI: 10.6084/m9.figshare.30247978
title: Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2+1 schedule

description: Clinical trials have compared new pneumococcal conjugative vaccines (PCVs; PCV15 and PCV20) to an established PCV (PCV13) in a routine 2 + 1 schedule. This study performed an indirect comparison of PCV15 vs. PCV20 immune responses in healthy infants and toddlers. Pooled, matching-adjusted PCV15 trials were indirectly compared to the analogous PCV20 trial for IgG response rate difference (RRD) and geometric mean concentration ratio (GMR) at the post-primary series (PPS) and post-toddler dose (PTD) timepoints. At PPS, PCV15 was non-inferior for RRD and GMR as compared to PCV20 for all PCV13 serotypes. Moreover, PCV15 was superior to PCV20 for the RRDs of serotypes 1, 3, 4, 5, 6B, 9V, and 23F and GMRs of serotypes 3, 4, 5, 6B, 9V, and 23F at PPS. At PTD, RRDs were comparable for all PCV13 serotypes, except serotype 3, for which PCV15 was superior. PCV15 was superior for the GMRs of serotypes 3, 6B, and 23F, and comparable for the remaining serotypes at PTD. RRDs for serotypes 22F and 33F were non-inferior at both PPS and PTD. In a 2 + 1 schedule, PCV15 demonstrates immunogenicity comparable or superior to PCV20 across PCV13 serotypes, especially for serotype 3.
DOI: 10.6084/m9.figshare.30247978.v2
title: Indirect comparison of the immunogenicity of 15-valent and 20-valent pneumococcal conjugate vaccines in children using a 2+1 schedule

description: Clinical trials have compared new pneumococcal conjugative vaccines (PCVs; PCV15 and PCV20) to an established PCV (PCV13) in a routine 2 + 1 schedule. This study performed an indirect comparison of PCV15 vs. PCV20 immune responses in healthy infants and toddlers. Pooled, matching-adjusted PCV15 trials were indirectly compared to the analogous PCV20 trial for IgG response rate difference (RRD) and geometric mean concentration ratio (GMR) at the post-primary series (PPS) and post-toddler dose (PTD) timepoints. At PPS, PCV15 was non-inferior for RRD and GMR as compared to PCV20 for all PCV13 serotypes. Moreover, PCV15 was superior to PCV20 for the RRDs of serotypes 1, 3, 4, 5, 6B, 9V, and 23F and GMRs of serotypes 3, 4, 5, 6B, 9V, and 23F at PPS. At PTD, RRDs were comparable for all PCV13 serotypes, except serotype 3, for which PCV15 was superior. PCV15 was superior for the GMRs of serotypes 3, 6B, and 23F, and comparable for the remaining serotypes at PTD. RRDs for serotypes 22F and 33F were non-inferior at both PPS and PTD. In a 2 + 1 schedule, PCV15 demonstrates immunogenicity comparable or superior to PCV20 across PCV13 serotypes, especially for serotype 3.
DOI: 10.6084/m9.figshare.29145345
title: Immunization information systems’ implementation and characteristics across the world: a systematic review of the literature

description: Immunization Information Systems (IISs) are essential public health tools, supporting the management and analysis of vaccination data to aid clinical and strategic decision-making. Following PRISMA guidelines, this systematic review investigated global state and operational characteristics of IISs. A comprehensive search across multiple databases up to 6<sup>th</sup> of June 2023, identified 2,612 articles, with 238 included. A significant increase in IIS research was observed in recent years, with a strong preference (84.5%) for electronic immunization registers (EIRs). Notably, 36% of IISs operate at the national level, and 47.7% meet the U.S. CDC definition, 17.0% are interoperable with personal health records, and 11.7% provide direct access to vaccination data for vaccinees or their guardians. Other key features include automated reminder systems for recipients and providers (12.1%), near real-time or real-time data entry (11.0%), the inclusion of demographic and socioeconomic data (16.7%), and the capacity to document vaccine refusal or hesitancy (10.2%). IISs contribute to improving population-level surveillance of vaccine-preventable diseases. Persistent limitations related to data standardization, interoperability, and cost-effectiveness evaluation must be addressed. Strengthening these aspects is crucial to fully harness the potential of IISs in various healthcare settings, where enhanced vaccination tracking and targeting are most urgently needed.
DOI: 10.6084/m9.figshare.29145345.v1
title: Immunization information systems’ implementation and characteristics across the world: a systematic review of the literature

description: Immunization Information Systems (IISs) are essential public health tools, supporting the management and analysis of vaccination data to aid clinical and strategic decision-making. Following PRISMA guidelines, this systematic review investigated global state and operational characteristics of IISs. A comprehensive search across multiple databases up to 6<sup>th</sup> of June 2023, identified 2,612 articles, with 238 included. A significant increase in IIS research was observed in recent years, with a strong preference (84.5%) for electronic immunization registers (EIRs). Notably, 36% of IISs operate at the national level, and 47.7% meet the U.S. CDC definition, 17.0% are interoperable with personal health records, and 11.7% provide direct access to vaccination data for vaccinees or their guardians. Other key features include automated reminder systems for recipients and providers (12.1%), near real-time or real-time data entry (11.0%), the inclusion of demographic and socioeconomic data (16.7%), and the capacity to document vaccine refusal or hesitancy (10.2%). IISs contribute to improving population-level surveillance of vaccine-preventable diseases. Persistent limitations related to data standardization, interoperability, and cost-effectiveness evaluation must be addressed. Strengthening these aspects is crucial to fully harness the potential of IISs in various healthcare settings, where enhanced vaccination tracking and targeting are most urgently needed.
DOI: 10.6084/m9.figshare.30730132
title: Incidence of stroke following COVID-19 vaccination: a nationwide self‑controlled risk interval study in Qatar

description: This study assessed short-term stroke risk following COVID-19 vaccination using Qatar’s national stroke registry and health platform. A self-controlled risk-interval study was conducted among individuals with stroke post-COVID-19 vaccination between 1 December 2020, and 11 April 2023. Stroke incidence during risk windows (0–21 and 22–42 days post-vaccination) was compared to a control window (43–180 days). Among 3,070 stroke cases, 685 met inclusion criteria. Stroke incidence was elevated in the 0–21-day window (IRR: 1.32; 95% CI: 1.07–1.63), but not in the 22–42-day window (IRR: 1.03; 95% CI: 0.82–1.30). Excess risk was estimated at 0.55 (95% CI: −0.04 to 1.01) strokes per 100,000 vaccine doses. IRRs for the 0–21-day window were 1.39 (95% CI: 1.08–1.80) for BNT162b2 and 1.15 (95% CI: 0.78–1.69) for mRNA-1273. By subtype, IRRs were 1.34 (95% CI: 1.07–1.68) for ischemic stroke, 1.11 (95% CI: 0.58–2.11) for hemorrhagic stroke, and 1.46 (95% CI: 0.38–5.56) for cerebral venous sinus thrombosis. A small, transient increase in stroke incidence was observed within 21 days of vaccination; however, such events remain exceedingly rare, with an estimated excess risk substantially lower than that typically associated with infection.
DOI: 10.6084/m9.figshare.30730132.v1
title: Incidence of stroke following COVID-19 vaccination: a nationwide self‑controlled risk interval study in Qatar

description: This study assessed short-term stroke risk following COVID-19 vaccination using Qatar’s national stroke registry and health platform. A self-controlled risk-interval study was conducted among individuals with stroke post-COVID-19 vaccination between 1 December 2020, and 11 April 2023. Stroke incidence during risk windows (0–21 and 22–42 days post-vaccination) was compared to a control window (43–180 days). Among 3,070 stroke cases, 685 met inclusion criteria. Stroke incidence was elevated in the 0–21-day window (IRR: 1.32; 95% CI: 1.07–1.63), but not in the 22–42-day window (IRR: 1.03; 95% CI: 0.82–1.30). Excess risk was estimated at 0.55 (95% CI: −0.04 to 1.01) strokes per 100,000 vaccine doses. IRRs for the 0–21-day window were 1.39 (95% CI: 1.08–1.80) for BNT162b2 and 1.15 (95% CI: 0.78–1.69) for mRNA-1273. By subtype, IRRs were 1.34 (95% CI: 1.07–1.68) for ischemic stroke, 1.11 (95% CI: 0.58–2.11) for hemorrhagic stroke, and 1.46 (95% CI: 0.38–5.56) for cerebral venous sinus thrombosis. A small, transient increase in stroke incidence was observed within 21 days of vaccination; however, such events remain exceedingly rare, with an estimated excess risk substantially lower than that typically associated with infection.
DOI: 10.6084/m9.figshare.29973536
title: Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies

description: Despite extensive efforts, global influenza vaccination rates remain suboptimal, particularly among high-risk populations. We conducted a comprehensive literature search up to April 2023. Experimental studies assessing the effectiveness of interventions on influenza vaccination uptake were included, expressed as risk ratios (RR) with 95% confidence intervals (CI). Random-effects meta-analysis models were utilized for pooled estimates, with heterogeneity assessed through I<sup>2</sup>. Subgroup analyses and meta-regressions were performed. This meta-analysis includes 180 studies involving 2,390,119 participants and comprehensively evaluates the effectiveness of recipient-, provider-, health system-based, and multitarget interventions. Overall, interventions significantly increased vaccination rates, with a pooled RR of 1.26 (95% CI, 1.21 to 1.32). Notably, provider-based interventions were more effective for healthcare workers (RR = 1.56; 95% CI, 1.46 to 1.66), whereas recipient-based interventions were more efficacious for pregnant women (RR = 1.42; 95% CI, 1.09 to 1.85). Multitarget strategies were the most effective among older adults (RR = 2.10; 95% CI, 1.61 to 2.72) and population under age of 18 (RR = 1.53; 95% CI, 1.23 to 1.90). These findings provide critical insights for optimizing public health strategies, underscoring the need for innovative and tailored approaches to enhance global vaccination uptake.
DOI: 10.6084/m9.figshare.29973536.v1
title: Enhancing influenza vaccination uptake: a systematic review and meta-analysis of intervention strategies

description: Despite extensive efforts, global influenza vaccination rates remain suboptimal, particularly among high-risk populations. We conducted a comprehensive literature search up to April 2023. Experimental studies assessing the effectiveness of interventions on influenza vaccination uptake were included, expressed as risk ratios (RR) with 95% confidence intervals (CI). Random-effects meta-analysis models were utilized for pooled estimates, with heterogeneity assessed through I<sup>2</sup>. Subgroup analyses and meta-regressions were performed. This meta-analysis includes 180 studies involving 2,390,119 participants and comprehensively evaluates the effectiveness of recipient-, provider-, health system-based, and multitarget interventions. Overall, interventions significantly increased vaccination rates, with a pooled RR of 1.26 (95% CI, 1.21 to 1.32). Notably, provider-based interventions were more effective for healthcare workers (RR = 1.56; 95% CI, 1.46 to 1.66), whereas recipient-based interventions were more efficacious for pregnant women (RR = 1.42; 95% CI, 1.09 to 1.85). Multitarget strategies were the most effective among older adults (RR = 2.10; 95% CI, 1.61 to 2.72) and population under age of 18 (RR = 1.53; 95% CI, 1.23 to 1.90). These findings provide critical insights for optimizing public health strategies, underscoring the need for innovative and tailored approaches to enhance global vaccination uptake.
DOI: 10.6084/m9.figshare.29062251
title: Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States

description: The U.S. Advisory Committee on Immunization Practices recommends use of bivalent stabilized prefusion F subunit vaccine (RSVpreF) among pregnant persons to protect their infants against lower respiratory tract illness due to RSV (RSV-LRTI). Using a cohort model depicting clinical outcomes and economic costs of RSV acute respiratory infection (RSV-ARI) among US infants from birth to age 1 year, we evaluated the impact of seasonally administered maternal RSVpreF versus no intervention. Outcomes included cases of medically attended RSV-ARI, RSV-related deaths, medical costs, and indirect costs. Costs were reported in 2023 US$. Among the 3.7 million US infants aged &lt;12 months each year, a total of 1,148,967 RSV-ARI cases (hospital: 48,384; emergency department [ED]: 246,118; outpatient clinic [OC]: 854,465) were projected to occur, yielding total annual costs of $2.4 billion (direct: $1.7B; indirect: $0.7B). With 54.9% uptake, RSVpreF would prevent 89,908 cases (hospital: 10,308; ED: 20,538; OC: 59,062), corresponding with a $368 million decrease (direct: $286 M; indirect: $81 M) in total 1-year costs. Even with limited uptake and without considering benefits to pregnant persons or reductions in RSV-related sequelae, maternal vaccination with RSVpreF would substantially reduce the public health and economic burden of RSV-ARI in US infants.
DOI: 10.6084/m9.figshare.29062251.v1
title: Potential public health and economic impact of maternal vaccination with bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine for the prevention of acute respiratory infection among infants in the United States

description: The U.S. Advisory Committee on Immunization Practices recommends use of bivalent stabilized prefusion F subunit vaccine (RSVpreF) among pregnant persons to protect their infants against lower respiratory tract illness due to RSV (RSV-LRTI). Using a cohort model depicting clinical outcomes and economic costs of RSV acute respiratory infection (RSV-ARI) among US infants from birth to age 1 year, we evaluated the impact of seasonally administered maternal RSVpreF versus no intervention. Outcomes included cases of medically attended RSV-ARI, RSV-related deaths, medical costs, and indirect costs. Costs were reported in 2023 US$. Among the 3.7 million US infants aged &lt;12 months each year, a total of 1,148,967 RSV-ARI cases (hospital: 48,384; emergency department [ED]: 246,118; outpatient clinic [OC]: 854,465) were projected to occur, yielding total annual costs of $2.4 billion (direct: $1.7B; indirect: $0.7B). With 54.9% uptake, RSVpreF would prevent 89,908 cases (hospital: 10,308; ED: 20,538; OC: 59,062), corresponding with a $368 million decrease (direct: $286 M; indirect: $81 M) in total 1-year costs. Even with limited uptake and without considering benefits to pregnant persons or reductions in RSV-related sequelae, maternal vaccination with RSVpreF would substantially reduce the public health and economic burden of RSV-ARI in US infants.
DOI: 10.18150/gxp4ri
title: Zagrożenia bezpieczeństwa związane z obszarami niepodlegającymi jurysdykcji państwowej - część 3

description: Zbiór zawiera dane zebrane w ramach projektu OPUS27 nr 2024/53/B/HS5/00272 pt. Zagrożenia bezpieczeństwa związane z obszarami niepodlegającymi jurysdykcji państwowej (Security threats related to areas beyond national jurisdiction) finansowanego przez Narodowe Centrum Nauki.Dokumenty zostały wykorzystane na potrzeby publikacji naukowej Agnieszka Szpak, Magdalena Redo, Joanna Rezmer, Karolina Gawron-Tabor, Jakub Kufel, Areas beyond national jurisdiction in the strategic documents of NATO and the EU – a comparative analysis, “Comparative Strategy”, 2025, DOI: 10.1080/01495933.2025.2571623.
DOI: 10.17026/ar/m9ewxq
title: PAN-00105084 - coin/coin-related, Quintillus (270)/Aurelianus (270- 275), voor Divus Claudius II, naar, antoninianus

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00105084&lt;/p&gt;
description: Modified: 2025-05-12T12:11:52+02:00
DOI: 10.15468/dl.cbb24n
title: Occurrence Download

description: A dataset containing 5 species occurrences available in GBIF matching the query:
{
 "DatasetKey" : [
 "is Catalogue of Life"
 ]
}

 The dataset includes 5 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0048649-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.17026/ar/o8qpzg
title: PAN-00176004 - wire brooch with stretched semi-circular bow

description: &lt;p&gt;This find is registered at Portable Antiquities of the Netherlands with number PAN-00176004&lt;/p&gt;
description: Modified: 2025-08-12T12:34:17+02:00